Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

A neuromodulation call to arms
Hagedorn, Jonathan M. , Hagedorn, Jonathan Michael, Hagedorn, Jonathan M

Mayo Clinic

Regional Anesthesia & Pain Medicine | March 26, 2019 | Volume: 44 | Issue: 4 | Pages: 532.1-532

10.1136/rapm-2018-100286 | PMID 30914476 Get It

PRN OPINION PAPER: Application of precision medicine across pharmacy specialty areas
Caudle, Kelly E. , Gammal, Roseann S., Karnes, Jason H. , Afanasjeva, Janna, Anderson, Keri C. , Frazee, Erin N. , Beavers, C. , Bhat, Shubha , Birrer, Kara L., Ensor, Christopher R. , Flowers, Stephanie A. , Formea, Christine M. , George, Jomy, Gosser, Rena , Karaoui, Lamis R. , Kolpek, Jimmi Hatton , Leung, Jonathan G. , Maldonado, Angela Q. , Minze, Molly G. , Pulk, Rebecca , Shelton, Chasity M. , Sheridan, Maria , Smith, Michael A. , Soefje, Scott A. , Tellez‐Corrales, Eglis , Walko, Christine M. , Leung, Jonathan G , Soefje, Scott A , Chahine, Elias B. , Hébert, Mary F. , Lee, James C. , Sheridan, Maria, Cavallari, Larisa H.

Mayo Clinic

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | March 25, 2019 | Volume: 2 | Issue: 3 | Pages: 288-302

10.1002/jac5.1107 Get It

Clinical pharmacists have been incorporating precision medicine into practice for decades. Drug selection and dosing based on patient‐specific clinical factors such as age, weight, renal function, drug interactions, plasma drug concentrations, and diet are expected as part of routine clinical practice. Newer concepts of precision medicine such as pharmacogenomics have recently been implemented into clinical care, while other concepts such as epigenetics and pharmacomicrobiomics still predominantly exist in the research area but clinical translation is expected in the future. The purpose of this paper is to describe current and emerging aspects of precision medicine as it relates to clinical pharmacy across a variety of specialty areas of practice, with perspectives from the American College of Clinical Pharmacy Practice and Research Network membership.
Outcomes of Adjuvant Radiotherapy Following Negative Surgical Margins for Cutaneous Squamous Cell Carcinoma
Chang, Timothy W., Peters, Margot S. , Baum, Christian L. , Peters, Margot, Miller, Jonathan M. , Schwartz, David Asa

Mayo Clinic

Dermatologic Surgery | March 24, 2019 | Volume: 45 | Issue: 9 | Pages: 1111-1116

10.1097/dss.0000000000001827 | PMID 30893176 Get It

BACKGROUND The role of adjuvant radiotherapy (ART) for cutaneous squamous cell carcinoma (cSCC) following negative surgical margins is unclear. OBJECTIVE To retrospectively examine the clinical outcomes in a cohort of patients with cSCC who completed ART after Mohs micrographic surgery or wide local excision with negative margins. METHODS AND MATERIALS After the institutional review board approval, a retrospective review was conducted of all patients with cSCC treated in the Mayo Clinic Department of Radiation Oncology from March 10, 1998, through April 26, 2013. Inclusion criteria were age >18 years, resection with negative histologic surgical margins, and completion of ART. RESULTS Thirty-two patients met the inclusion criteria: 15 patients died, 12 without evidence of disease related to cSCC. Three patients developed recurrent disease, all with poorly differentiated cSCC, > 2 cm in clinical diameter, perineural invasion, and Brigham and Women's (BWH) stage T2b/T3; 2 of 3 patients were immunosuppressed; and 2 of 3 patients died of cSCC-related causes. CONCLUSION These data suggest that the combination of surgical resection and ART is a reasonable option for Brigham and Women's T2b/T3 tumors.
A Bayesian Approach to Multistate Hidden Markov Models: Application to Dementia Progression
Williams, Jonathan , Storlie, Curtis B. , Therneau, Terry M. , Jack, Clifford R. , Hannig, Jan , Jack, Clifford R , Williams, Jonathan P

Mayo Clinic

Journal of the American Statistical Association | March 21, 2019 | Volume: 115 | Issue: 529 | Pages: 16-31

10.1080/01621459.2019.1594831 Get It

Go for the Gold: A “Plane” and Simple Technique for Resecting Benign Peripheral Nerve Sheath Tumors
Stone, Jonathan J. , Spinner, Robert J.

Mayo Clinic

Operative Neurosurgery | March 19, 2019 | Volume: 18 | Issue: 1 | Pages: 60-68

10.1093/ons/opz034 | PMID 30888029 Get It

Abstract BACKGROUND Intraneural dissection is a useful technique for achieving gross total resection and preserving functional fascicles for peripheral nerve tumors. Finding the correct tissue plane is the critical step for safe successful enucleation. The authors hypothesized that the yellow color of benign nerve tumors can be used to identify surgical planes. OBJECTIVE To describe a technique to find the correct intraneural dissection plane based on a quantified yellow appearance during resection of benign peripheral nerve sheath tumors. METHODS Intraoperative photographs were reviewed to determine the percentage of yellow that tumors appeared at different phases of surgery. A technique was developed to quantitatively measure the amount of yellow using Photoshop. Previously published journal articles containing color images of peripheral nerve tumor resections were also analyzed for yellow tumor color. RESULTS There were 24 patients with suitable images to permit measurement of color for 3 steps of the procedure. The average percentages of yellow for tumor exposure, tumor resection, and removed specimen were 36.5%, 59.1%, and 80.4%, respectively ( P < .001). Three publications were found that contained high-quality images of at least 2 phases of the surgery with average yellow content of 47.4% and 84% ( P < .01). CONCLUSION The simple observation that a benign nerve sheath tumor is yellow in color can be used to guide surgical resection and achieve excellent outcomes. Intraneural dissection through the pseudocapsule should be pursued layer by layer until a yellow true capsule is found. By sparing functional nervous tissue within the pseudocapsule, this technique may lead to improved neurological outcomes.
Completion lymphadenectomy for a positive sentinel node biopsy in melanoma patients is not associated with a survival benefit
Klemen, Nicholas D. , Leong, Stanley P. L. , Kashani–Sabet, Mohammed , Vetto, John T. , White, Richard L. , Schneebaum, Schlomo , Pockaj, Barbara A. , Mozzillo, Nicola, Charney, Kim, Hoekstra, Harald J. , Sondak, Vernon K. , Messina, Jane L. , Han, Dale , White, Richard , Pockaj, Barbara, Han, Dale , Han, Gang , Zager, Jonathan S.

Mayo Clinic

Journal of Surgical Oncology | March 18, 2019 | Volume: 119 | Issue: 8 | Pages: 1053-1059

10.1002/jso.25444 | PMID 30883771 Get It

AbstractBackgroundCompletion lymph node dissection (CLND) for sentinel lymph node (SLN) disease in melanoma patients is debated. We evaluated the impact of CLND on survival and assessed for predictors of nonsentinel node metastasis (positive CLND).MethodsPositive SLN melanoma patients were retrospectively identified in the Sentinel Lymph Node Working Group database. Clinicopathological factors were correlated with CLND status, overall survival (OS), and melanoma‐specific survival (MSS).ResultsThere were 953 positive SLN patients of whom 831 (87%) had CLND. Positive CLND was seen in 141 (17%) cases and was associated with worse OS and MSS (both P < 0.001). CLND was not performed (No‐CLND) in 122 of 953 positive SLN cases (13%), of whom 100 had follow‐up and 18 (18%) developed a nodal recurrence (NR). No significant differences in OS and MSS were seen comparing CLND with No‐CLND (P = 0.084, P = 0.161, respectively) and comparing positive CLND with No‐CLND NR patients (P = 0.565, P = 0.998, respectively). Gender, primary site, ulceration, and number of positive SLNs were correlated with nonsentinel node metastasis.ConclusionsPerformance of CLND provides prognostic information but is not associated with a survival benefit. Clinical variables can predict a positive CLND in patients who may be at high risk of recurrence.
Mental Health Disorders are More Common in Colorectal Cancer Survivors and Associated With Decreased Overall Survival
Baraghoshi, David , Garrido‐Laguna, Ignacio , Gilcrease, Glynn Weldon, Whisenant, Jonathan, Weis, John R., Scaife, Courtney L. , Pickron, T. Bartley, Huang, Lyen C. , Monroe, Marcus M. , Abdelaziz, Sarah, Fraser, Alison , Deshmukh, Vikrant , Rowe, Kerry , Snyder, John , Samadder, N. Jewel , Hashibe, Mia, Samadder, Niloy J, Lloyd, Shane , Tao, Randa , Smith, Ken R. , Newman, Michael , Snyder, John

Mayo Clinic

American Journal of Clinical Oncology | March 18, 2019 | Volume: 42 | Issue: 4 | Pages: 355-362

10.1097/coc.0000000000000529 | PMID 30844850 Get It

Objectives: To determine the risk and risk factors for mental illness among colorectal cancer (CRC) survivors across short-term and long-term follow-up periods. Methods: We used the Utah Cancer Registry to identify CRC survivors diagnosed between 1997 and 2013. Mental health diagnoses were available in electronic medical records and statewide facilities data that were linked by the Utah Population Database. CRC survivors were matched to individuals from a general population cohort. The risk of developing a mental illness was compared between cohorts. The association between mental illness and mortality was also analyzed. Results: In total, 8961 CRC survivors and 35,897 individuals in a general population cohort were identified. CRC survivors were at increased risk for any mental health diagnosis at 0 to 2 years (hazard ratio [HR], 3.70; 95% confidence interval [CI], 3.47-3.95), >2 to 5 years (HR, 1.23; 95% CI, 1.09-1.38), and >5 years (HR, 1.20; 95% CI, 1.07-1.36) after cancer diagnosis. CRC survivors were also at increased risk of depressive disorders specifically during the same time periods. At >5 years, CRC survivors still had an increased risk of developing many mental health diagnoses. Factors associated with increased risk of any mental health disorder among CRC survivors included colostomy and Charlson Comorbidity Index of 1+. There was an increased risk of death for CRC survivors diagnosed with any mental health disorder (HR, 2.18; 95% CI, 2.02-2.35) and depression (HR, 2.10; 95% CI, 1.92-2.28). Conclusions: CRC survivors are at increased risk for mental health disorders in the short-term and long-term. Survivors who develop mental health disorders also experience decreased survival.
Higher order genomic organization and epigenetic control maintain cellular identity and prevent breast cancer
Fritz, Andrew J. , Gerrard, Diana L., Hong, David I. , Rose, Joshua T., Ghule, Prachi N. , Bolf, Eric L. , Gordon, Jonathan , Tracy, Kirsten M. , Nickerson, Jeffrey A. , Wijnen, André J. van , Imbalzano, Anthony N. , Heath, Jessica L. , Frietze, Seth , Zaidi, Sayyed K. , Carr, Frances E. , Lian, Jane B. , Stein, Janet L. , Fritz, A J , Stein, Gary S , van Wijnen, Andre J , Tracy, Kirsten M , Gillis, Noelle E. , Rodriguez, Princess D. , Hong, D., Gordon, J.A., Tye, Coralee E. , Boyd, Joseph R. , Stein, Gary S.

Mayo Clinic

Genes, Chromosomes and Cancer | March 15, 2019 | Volume: 58 | Issue: 7 | Pages: 484-499

10.1002/gcc.22731 | PMID 30873710 Get It

Cells establish and sustain structural and functional integrity of the genome to support cellular identity and prevent malignant transformation. In this review, we present a strategic overview of epigenetic regulatory mechanisms including histone modifications and higher order chromatin organization (HCO) that are perturbed in breast cancer onset and progression. Implications for dysfunctions that occur in hormone regulation, cell cycle control, and mitotic bookmarking in breast cancer are considered, with an emphasis on epithelial‐to‐mesenchymal transition and cancer stem cell activities. The architectural organization of regulatory machinery is addressed within the contexts of translating cancer‐compromised genomic organization to advances in breast cancer risk assessment, diagnosis, prognosis, and identification of novel therapeutic targets with high specificity and minimal off target effects.